IN2014DN05772A - - Google Patents
Info
- Publication number
- IN2014DN05772A IN2014DN05772A IN5772DEN2014A IN2014DN05772A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A IN 5772DEN2014 A IN5772DEN2014 A IN 5772DEN2014A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A
- Authority
- IN
- India
- Prior art keywords
- galectin
- medicament
- novel compounds
- compounds
- ligandsin
- Prior art date
Links
- 102000007563 Galectins Human genes 0.000 abstract 3
- 108010046569 Galectins Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- -1 propargyl D galactopyranoside derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12152413.6A EP2620443A1 (en) | 2012-01-25 | 2012-01-25 | Novel galactoside inhibitors of galectins |
| PCT/EP2013/051339 WO2013110704A1 (en) | 2012-01-25 | 2013-01-24 | Novel galactoside inhibitors of galectins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05772A true IN2014DN05772A (enExample) | 2015-04-10 |
Family
ID=47598867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5772DEN2014 IN2014DN05772A (enExample) | 2012-01-25 | 2013-01-24 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9353141B2 (enExample) |
| EP (2) | EP2620443A1 (enExample) |
| JP (1) | JP6158840B2 (enExample) |
| CN (1) | CN104066743B (enExample) |
| CA (1) | CA2854986C (enExample) |
| ES (1) | ES2559857T3 (enExample) |
| IN (1) | IN2014DN05772A (enExample) |
| WO (1) | WO2013110704A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| IL149139A0 (en) | 1999-11-03 | 2002-11-10 | Bristol Myers Squibb Co | Pharmaceutical compositions containing metformin and glyburide |
| US9243021B2 (en) | 2012-10-31 | 2016-01-26 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| WO2014078655A1 (en) * | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| JP2016507503A (ja) | 2012-12-20 | 2016-03-10 | ヘンリー フォード ヘルス システム | ガレクチン−３を阻害することによる拡張期心不全を治療する方法 |
| US12390486B2 (en) | 2012-12-20 | 2025-08-19 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| EP3415522A1 (en) * | 2014-07-09 | 2018-12-19 | Galecto Biotech AB | Novel hybrid galactoside inhibitor of galectins |
| EP3828191A3 (en) * | 2015-01-30 | 2021-08-18 | Galecto Biotech AB | Novel galactoside inhibitor of galectins |
| EP3423461A4 (en) * | 2016-03-04 | 2020-03-25 | Galectin Sciences, LLC | SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THEIR USE |
| WO2018011094A1 (en) * | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| EP3484903A1 (en) * | 2016-07-12 | 2019-05-22 | Galecto Biotech AB | Alpha-d-galactoside inhibitors of galectins |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THEIR USE |
| WO2019133878A1 (en) | 2017-12-29 | 2019-07-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| CA3102155A1 (en) | 2018-06-29 | 2020-01-02 | Glykos Biomedical Oy | Conjugates |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| EP3902797A1 (en) | 2018-12-27 | 2021-11-03 | GlycoMimetics, Inc. | Galectin-3 inhibiting c-glycosides |
| JP7612663B2 (ja) * | 2019-08-09 | 2025-01-14 | イドルシア・ファーマシューティカルズ・リミテッド | （２－アセタミジル）チオ－ベータ－ｄ－ガラクトピラノシド誘導体 |
| WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
| CN116270672A (zh) * | 2023-02-27 | 2023-06-23 | 江苏科技大学 | β-D-硫代葡萄糖钠盐在制备缓解或治疗急性肾损伤的药物中的应用 |
| CZ2023132A3 (cs) | 2023-04-04 | 2024-10-16 | Ústav Chemických Procesů Av Čr, V. V. I. | Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) * | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| CN102066393B (zh) | 2008-05-16 | 2014-07-02 | 格莱克特生物技术公司 | 半乳糖苷抑制剂的合成 |
| WO2010126435A1 (en) | 2009-04-28 | 2010-11-04 | Forskarpatent I Syd Ab | Novel galactoside inhibitors of galectins |
| ES2817888T3 (es) | 2012-10-31 | 2021-04-08 | Galecto Biotech Ab | Inhibidor de galactósido de galectina-3 y su uso para tratar fibrosis pulmonar |
-
2012
- 2012-01-25 EP EP12152413.6A patent/EP2620443A1/en not_active Withdrawn
-
2013
- 2013-01-24 CA CA2854986A patent/CA2854986C/en not_active Expired - Fee Related
- 2013-01-24 CN CN201380006432.7A patent/CN104066743B/zh not_active Expired - Fee Related
- 2013-01-24 WO PCT/EP2013/051339 patent/WO2013110704A1/en not_active Ceased
- 2013-01-24 ES ES13700935.3T patent/ES2559857T3/es active Active
- 2013-01-24 JP JP2014553715A patent/JP6158840B2/ja not_active Expired - Fee Related
- 2013-01-24 US US14/364,169 patent/US9353141B2/en not_active Expired - Fee Related
- 2013-01-24 EP EP13700935.3A patent/EP2807176B1/en not_active Not-in-force
- 2013-01-24 IN IN5772DEN2014 patent/IN2014DN05772A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140336146A1 (en) | 2014-11-13 |
| CA2854986A1 (en) | 2013-08-01 |
| JP2015504909A (ja) | 2015-02-16 |
| ES2559857T3 (es) | 2016-02-16 |
| CA2854986C (en) | 2019-09-17 |
| CN104066743A (zh) | 2014-09-24 |
| US9353141B2 (en) | 2016-05-31 |
| EP2620443A1 (en) | 2013-07-31 |
| EP2807176A1 (en) | 2014-12-03 |
| WO2013110704A1 (en) | 2013-08-01 |
| CN104066743B (zh) | 2016-04-06 |
| EP2807176B1 (en) | 2015-12-30 |
| JP6158840B2 (ja) | 2017-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05772A (enExample) | ||
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MY160241A (en) | 5-alkynyl-pyrimidines | |
| EA024702B8 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| MD20140002A2 (ro) | Indazoli | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| NZ705135A (en) | Heteroaryl compounds and methods of use thereof | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| PH12015501116A1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
| IN2014MN02459A (enExample) | ||
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| HK1211947A1 (en) | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | |
| PH12015500211A1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
| UA111628C2 (uk) | Композиція для боротьби з хворобою рослини та її застосування | |
| MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| IN2015DN01151A (enExample) | ||
| MX2014004858A (es) | Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas. | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX340577B (es) | Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc. | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| MX2014002988A (es) | Proceso y composicion para inhibir la polimerizacion de compuestos de ciclopentadieno. | |
| TN2012000469A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. |